Diabetes Metab J.  2023 Nov;47(6):882-883. 10.4093/dmj.2023.0355.

Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)

• Scherbak NN
• Kruse R
• Nyström T
• Jendle J

• KMID: 2548165
• DOI: http://doi.org/10.4093/dmj.2023.0355

Reference

1. Scherbak NN, Kruse R, Nystrom T, Jendle J. Glimepiride compared to liraglutide increases plasma levels of miR-206, miR-182-5p, and miR-766-3p in type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab J. 2023; 47:668–81.

2. Barbagallo D, Piro S, Condorelli AG, Mascali LG, Urbano F, Parrinello N, et al. miR-296-3p, miR-298-5p and their downstream networks are causally involved in the higher resistance of mammalian pancreatic α cells to cytokine-induced apoptosis as compared to β cells. BMC Genomics. 2013; 14:62.

3. Guay C, Regazzi R. New emerging tasks for microRNAs in the control of β-cell activities. Biochim Biophys Acta. 2016; 1861(12 Pt B):2121–9.

4. Demirsoy IH, Ertural DY, Balci S, Cinkir U, Sezer K, Tamer L, et al. Profiles of circulating miRNAs following metformin treatment in patients with type 2 diabetes. J Med Biochem. 2018; 37:499–506.

5. Li X, Li Y, Zhao L, Zhang D, Yao X, Zhang H, et al. Circulating muscle-specific miRNAs in Duchenne muscular dystrophy patients. Mol Ther Nucleic Acids. 2014; 3:e177.

6. Toivonen JM, Manzano R, Olivan S, Zaragoza P, Garcia-Redondo A, Osta R. MicroRNA-206: a potential circulating biomarker candidate for amyotrophic lateral sclerosis. PLoS One. 2014; 9:e89065.

7. Liu X, Zheng W, Zhang X, Dong M, Sun G. The diagnostic and prognostic value of serum miR-206 in colorectal cancer. Int J Clin Exp Pathol 2017;10:7528-33. 8. Jin P, Gu W, Lai Y, Zheng W, Zhou Q, Wu X. The circulating microRNA-206 level predicts the severity of pulmonary hypertension in patients with left heart diseases. Cell Physiol Biochem. 2017; 41:2150–60.

9. Zhu L, Chen T, Ye W, Wang JY, Zhou JP, Li ZY, et al. Circulating miR-182-5p and miR-5187-5p as biomarkers for the diagnosis of unprotected left main coronary artery disease. J Thorac Dis. 2019; 11:1799–808.

10. FDA Center for Drug Evaluation and Research. Biomarker qualification: evidentiary framework (FDA-2018-D-4267). Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biomarker-qualification-evidentiary-framework (cited 2023 Oct 12).